제품 > 항체 > Biosimilar Antibody

Human IL-1β Monoclonal Antibody (YR0006)

Direct ELISA binding curve demonstrating the recognition of Human Anti-Human IL-1β (Research Grade Canakinumab Biosimilar) Monoclonal Antibody to IL-1β. The target protein was coated onto the microplate well surface, followed by binding of the antibody. A donkey anti-human IgG HRP conjugate was used for detection.

Human IL-1β SPR assay. Determined through SPR assay, the Human Anti-Human IL-1β (Research Grade Canakinumab Biosimilar) Monoclonal Antibody is capable of binding to Human IL-1β with an affinity constant of 0.1067 nM.

Basic Information

Clone	Canakinumab Biosimilar
Molecular Weight	150 kDa
Endotoxin	<1EU/mg (<0.001EU/μg)Determined by LAL gel clotting assay
Sterility	0.2 μm filtration
Aggregation	<5% Determined by SECP
Purity	>95% Determined by SDS-PAGE

Product Information

Production	Purified from cell culture supernatant in an animal-free facility
Purification	Protein A or G purification
Storage	2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing)

Target Background

Canakinumab is a recombinant human monoclonal antibody which binds to IL-1β (interleukin-1 beta). It’s mode of action is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation in patients with disorders of autoimmune origin. In June 2009, the FDA approved canakinumab for the treatment of cryopyrin-associated periodic syndromes (CAPS), a spectrum of autoinflammatory syndromes. In September 2016, the FDA approved it’s use for three additional rare and serious auto-inflammatory diseases: tumor necrosis factor receptor associated periodic syndrome (TRAPS), hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD), and familial Mediterranean fever (FMF). In June 2020, canakinumab was FDA-approved for the indication to treat active Still's disease, including adult-onset Still's disease (AOSD).